Alnylam Pharmace. buy The Goldman Sachs Group, Inc.
Start price
16.09.25
/
50%
€388.70
Target price
16.09.26
€480.99
Performance (%)
-35.40%
Price
22:25
€251.10
Summary
This prediction is currently active. The BUY prediction by The_Goldman_Sachs_Gr for Alnylam Pharmace. is performing very badly with a performance of -35.40%. This prediction currently runs until 16.09.26. The prediction end date can be changed by The_Goldman_Sachs_Gr at any time. The_Goldman_Sachs_Gr has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
AI-generated
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Alnylam Pharmace. | 6.515% | 6.515% |
| iShares Core DAX® | 1.717% | 3.368% |
| iShares Nasdaq 100 | -4.565% | -4.238% |
| iShares Nikkei 225® | -7.120% | -11.869% |
| iShares S&P 500 | -0.894% | 1.687% |
Comments by The_Goldman_Sachs_Gr for this prediction
In the thread Alnylam Pharmace. diskutieren
Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $504.00 to $566.00. They now have a "buy" rating on the stock.
Ratings data for ALNY provided by MarketBeat
Stopped prediction by The_Goldman_Sachs_Gr for Alnylam Pharmace.
Alnylam Pharmace.
Start price
Target price
Perf. (%)
€240.00
16.08.24
16.08.24
€336.33
16.08.25
16.08.25
58.83%
17.08.25
17.08.25
